Exosomal miR‐3131 derived from endothelial cells with KRAS mutation promotes EndMT by targeting PICK1 in brain arteriovenous malformations

Abstract

AbstractAimsTo explore the underlying mechanism by which low‐frequency KRAS mutations result in extensive EndMT occurrence.MethodsExosomes derived from primarily cultured brain arteriovenous malformation (bAVMs) and human umbilical vein endothelial cells (HUVECs) transfected with KRASG12D, KRASWT, or KRASNC lentiviruses were isolated, and their effects on HUVECs were identified by western blotting and immunofluorescence staining. The expression levels of exosomal microRNAs (miRNAs) were evaluated by miRNA microarray, followed by functional experiments on miR‐3131 and detection of its downstream target, and miR‐3131 inhibitor in reversing the EndMT process induced by KRASG12D‐transfected HUVECs and bAVM endothelial cells (ECs) were explored.ResultsExosomes derived from KRASG12D bAVM ECs and KRASG12D‐transfected HUVECs promoted EndMT in HUVECs. MiR‐3131 levels were highest in the exosomes of KRASG12D‐transfected HUVECs, and HUVECs transfected with the miR‐3131 mimic acquired mesenchymal phenotypes. RNA‐seq and dual‐luciferase reporter assays revealed that PICK1 is the direct downstream target of miR‐3131. Exosomal miR‐3131 was highly expressed in KRASG12D bAVMexos compared with non‐KRAS‐mutant bAVMexos or HUVECexos. Finally, a miR‐3131 inhibitor reversed EndMT in HUVECs treated with exosomes or the supernatant of KRASG12D‐transfected HUVECs and KRASG12D bAVM ECs.ConclusionExosomal miR‐3131 promotes EndMT in KRAS‐mutant bAVMs, and miR‐3131 might be a potential biomarker and therapeutic target in KRASG12D‐mutant bAVMs.